TRI-SPRINTEC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRI-SPRINTEC (TRI-SPRINTEC).
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation, and increases viscosity of cervical mucus to inhibit sperm penetration.
| Metabolism | Ethinyl estradiol is metabolized by CYP3A4 and undergoes conjugation; norgestimate is metabolized to norelgestromin and levonorgestrel primarily by CYP3A4 and other enzymes. |
| Excretion | Renal: 50% (metabolites); Fecal: 35% (eliminated in bile); unchanged drug <1%. |
| Half-life | Norelgestromin: 28 hours; Ethinyl estradiol: 17 hours. Steady-state achieved within 7 days. |
| Protein binding | Norelgestromin: 97% bound to albumin and SHBG; Ethinyl estradiol: 98% bound to albumin. |
| Volume of Distribution | Norelgestromin: 2.4 L/kg; Ethinyl estradiol: 2.9 L/kg. Indicates extensive tissue distribution. |
| Bioavailability | Transdermal: 100% (systemic absorption rate similar to oral). |
| Onset of Action | Transdermal: 48 hours for full contraceptive effect; patch applied weekly. |
| Duration of Action | Contraceptive protection maintained for 7 days of patch wear; resumed after patch-free week. |
One tablet (0.035 mg ethinyl estradiol / 0.250 mg norgestimate) orally once daily for 21 days, followed by 7 days of placebo tablets. Repeat cycle.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment required for renal impairment. Use with caution in women with severely impaired renal function due to potential estrogen-related fluid retention. |
| Liver impairment | Contraindicated in acute hepatitis, severe cirrhosis, or liver tumors. For mild hepatic impairment (Child-Pugh A), use with caution; no specific dose adjustment. Avoid in moderate to severe impairment. |
| Pediatric use | Not indicated for use before menarche. For post-menarchal adolescents, same dosing as adults (0.035/0.250 mg daily). Ensure adequate bone mineral density and growth monitoring. |
| Geriatric use | Not indicated for post-menopausal women. Contraindicated in women over 35 who smoke due to increased cardiovascular risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRI-SPRINTEC (TRI-SPRINTEC).
| Breastfeeding | Excreted in breast milk in small amounts; ethinyl estradiol and norgestimate M/P ratio ~0.1-0.5. May reduce milk production and nutrient content (protein, fat). Not recommended during breastfeeding; use alternative contraception if breastfeeding. |
| Teratogenic Risk | Pregnancy category X. Tri-Sprintec (ethinyl estradiol and norgestimate) is contraindicated in pregnancy due to teratogenic effects from sex hormones. First trimester: Increased risk of non-cardiac birth defects, limb reduction defects, and neural tube defects; discontinue immediately if pregnancy occurs. Second and third trimesters: Associated with masculinization of female fetuses (from progestin), urogenital sinus abnormalities, and potential long-term metabolic effects; use during organogenesis carries highest risk. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Women over 35 who smoke are strongly advised not to use this product.
| Serious Effects |
["Thrombophlebitis or thromboembolic disorders","History of deep vein thrombosis or pulmonary embolism","Cerebrovascular or coronary artery disease","Known or suspected breast cancer","Carcinoma of endometrium or other estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior pill use","Hepatic adenoma or carcinoma","Known or suspected pregnancy","Hypersensitivity to any component","Cigarette smoking in women over 35","Uncontrolled hypertension","Diabetes with vascular involvement","Headaches with focal neurological symptoms","Major surgery with prolonged immobilization"]
| Precautions | ["Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction)","Hepatic neoplasia (benign and malignant)","Elevated blood pressure","Gallbladder disease","Carbohydrate and lipid metabolic effects","Headache/migraine","Irregular bleeding","Depression","Carcinoma of breast and cervix","Ocular lesions"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of early pregnancy (β-hCG) before initiation and during use. If pregnancy occurs, discontinue immediately and counsel on risks. No routine fetal monitoring required; however, if accidental exposure, consider detailed fetal ultrasound for anomaly detection. |
| Fertility Effects | Suppresses ovulation, impairing fertility during use. After discontinuation, fertility typically returns rapidly within 1-3 months. No permanent negative effects on fertility documented. |